Advertisement

Topics

ASLAN Announces First Patient Enrolled In A Global Phase II/III Study For Varlitinib In Gastric Cancer

20:00 EDT 30 Aug 2017 | BioSpace

Singapore, 31 August 2017 ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the enrolment of the first patient in a global phase 2/3 study investigating varlitinib as first line therapy in HER1/HER2 co-expressing advanced or metastatic gastr...

Original Article: ASLAN Announces First Patient Enrolled In A Global Phase II/III Study For Varlitinib In Gastric Cancer

NEXT ARTICLE

More From BioPortfolio on "ASLAN Announces First Patient Enrolled In A Global Phase II/III Study For Varlitinib In Gastric Cancer"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...